Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-?B pathway

被引:8
作者
Yan, Bao-Fei [1 ]
Pan, Lan-Fen [2 ]
Quan, Yi-Fang [3 ]
Sha, Qian [4 ]
Zhang, Jing-Zheng [1 ]
Zhang, Yi-Feng [5 ]
Zhou, Li-Bing [6 ]
Qian, Xi-Long [7 ]
Gu, Xiao-Mei [6 ]
Li, Feng-Tao [1 ]
Wang, Ting [6 ]
Liu, Jia [1 ]
Zheng, Xian [6 ,8 ]
机构
[1] Jiangsu Hlth Vocat Coll, Coll Pharm, Nanjing 211800, Jiangsu, Peoples R China
[2] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Pathol, Kunshan 215300, Jiangsu, Peoples R China
[3] First Peoples Hosp Taicang, Dept Educ & Sci, Kunshan 215400, Jiangsu, Peoples R China
[4] Xuzhou Med Univ, Affiliated Hosp, Dept Pharm, Xuzhou 221006, Jiangsu, Peoples R China
[5] Nantong Univ, Sch Pharm, Nantong 226019, Jiangsu, Peoples R China
[6] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Pharm, Kunshan 215300, Jiangsu, Peoples R China
[7] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China
[8] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Pharm, 566 Qianjin East Rd, Kunshan 215300, Jiangsu, Peoples R China
关键词
Nonalcoholic fatty liver disease; Huangqin decoction; Lipid metabolism disorders; Insulin resistance; Sirt1/NF-& kappa; B pathway; NECROSIS-FACTOR-ALPHA; LONG-TERM; FOLLOW-UP; STEATOHEPATITIS; PATHOGENESIS; INFLAMMATION; NAFLD; DIET;
D O I
10.3748/wjg.v29.i31.4744
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUNDNonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, making it the most common cause of chronic liver disease globally. Huangqin decoction (HQD), a Chinese medicinal formulation that has been used clinically for thousands of years, has beneficial outcomes in patients with liver diseases, including NAFLD. However, the role and mechanism of action of HQD in lipid metabolism disorders and insulin resistance in NAFLD remain poorly understood.AIMTo evaluate the ameliorative effects of HQD in NAFLD, with a focus on lipid metabolism and insulin resistance, and to elucidate the underlying mechanism of action.METHODSHigh-fat diet-induced NAFLD rats and palmitic acid (PA)-stimulated HepG2 cells were used to investigate the effects of HQD and identify its potential mechanism of action. Phytochemicals in HQD were analyzed by high-performance liquid chromatography (HPLC) to identify the key components.RESULTSTen primary chemical components of HQD were identified by HPLC analysis. In vivo, HQD effectively prevented rats from gaining body and liver weight, improved the liver index, ameliorated hepatic histological aberrations, decreased transaminase and lipid profile disorders, and reduced the levels of pro-inflammatory factors and insulin resistance. In vitro studies revealed that HQD effectively alleviated PA-induced lipid accumulation, inflammation, and insulin resistance in HepG2 cells. In-depth investigation revealed that HQD triggers Sirt1/NF-?B pathway-modulated lipogenesis and inflammation, contributing to its beneficial actions, which was further corroborated by the addition of the Sirt1 antagonist EX-527 that compromised the favorable effects of HQD.CONCLUSIONIn summary, our study confirmed that HQD mitigates lipid metabolism disorders and insulin resistance in NAFLD by triggering the Sirt1/NF-?B pathway.
引用
收藏
页码:4744 / 4762
页数:19
相关论文
共 59 条
  • [1] Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatiosis in patients with non-alcoholic fatty liver disease
    Araya, J
    Rodrigo, R
    Videla, LA
    Thielemann, L
    Orellana, M
    Pettinelli, P
    Poniachik, J
    [J]. CLINICAL SCIENCE, 2004, 106 (06) : 635 - 643
  • [2] The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver
    Badolati, Nadia
    Masselli, Raffaello
    Sommella, Eduardo
    Sagliocchi, Serena
    Di Minno, Alessandro
    Salviati, Emanuela
    Campiglia, Pietro
    Dentice, Monica
    Tenore, Gian Carlo
    Stornaiuolo, Mariano
    Novellino, Ettore
    [J]. ANTIOXIDANTS, 2020, 9 (05)
  • [3] The interaction of hepatic lipid and glucose metabolism in liver diseases
    Bechmann, Lars P.
    Hannivoort, Rebekka A.
    Gerken, Guido
    Hotamisligil, Goekhan S.
    Trauner, Michael
    Canbay, Ali
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (04) : 952 - 964
  • [4] Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver
    Boden, G
    She, PX
    Mozzoli, M
    Cheung, P
    Gumireddy, K
    Reddy, P
    Xiang, XQ
    Luo, ZJ
    Ruderman, N
    [J]. DIABETES, 2005, 54 (12) : 3458 - 3465
  • [5] The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
    Buzzetti, Elena
    Pinzani, Massimo
    Tsochatzis, Emmanuel A.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1038 - 1048
  • [6] SIRT1 and insulin resistance
    Cao, Yue
    Jiang, Xinli
    Ma, Huijie
    Wang, Yuling
    Xue, Peng
    Liu, Yan
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (01) : 178 - 183
  • [7] Gallic Acid Ameliorated Impaired Lipid Homeostasis in a Mouse Model of High-Fat Diet-and Streptozotocin-Induced NAFLD and Diabetes through Improvement of β-oxidation and Ketogenesis
    Chao, Jung
    Cheng, Hao-Yuan
    Chang, Ming-Ling
    Huang, Shyh-Shyun
    Liao, Jiunn-Wang
    Cheng, Yung-Chi
    Peng, Wen-Huang
    Pao, Li-Heng
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [8] Scutellaria baicalensis regulates FFA metabolism to ameliorate NAFLD through the AMPK-mediated SREBP signaling pathway
    Chen, Qian
    Liu, Mengyang
    Yu, Haiyang
    Li, Jian
    Wang, Sijian
    Zhang, Yi
    Qiu, Feng
    Wang, Tao
    [J]. JOURNAL OF NATURAL MEDICINES, 2018, 72 (03) : 655 - 666
  • [9] Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters
    Cobbina, Enoch
    Akhlaghi, Fatemeh
    [J]. DRUG METABOLISM REVIEWS, 2017, 49 (02) : 197 - 211
  • [10] Final results of a long-term, clinical follow-up in fatty liver patients
    Dam-Larsen, Sanne
    Becker, Ulrik
    Franzmann, Maria-Benedicte
    Larsen, Klaus
    Christoffersen, Per
    Bendtsen, Flemming
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (10) : 1236 - 1243